<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342470</url>
  </required_header>
  <id_info>
    <org_study_id>PMK-S005_Phase II</org_study_id>
    <nct_id>NCT02342470</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled, Dose-finding, Phase IIa Clinical Trial to Efficacy and Safety of PMK-S005 for the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaKing</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaKing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety by comparing prevention of
      recurrent peptic ulcer in low-dose aspirin users between PMK-S005 and Placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 24, 2014</start_date>
  <completion_date type="Actual">December 8, 2017</completion_date>
  <primary_completion_date type="Actual">December 8, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of endoscopic peptic ulcer</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of endoscopic stomach / duodenal mucosal disease(erosion, ulcer)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of endoscopic stomach / duodenal erosion</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of endoscopic stomach / duodenal ulcer</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of MLS in the gastroduodenal endoscopy result compared to baseline</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of endoscopic esophagitis</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue drug use count and the total amount</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gastrointestinal symptoms score</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator / Bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PMK-S005 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 50mg, by mouth, bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PMK-S005 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 100mg, by mouth, bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PMK-S005 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 150mg, by mouth, bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug : Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PMK-S005 1</intervention_name>
    <description>Drug : PMK-S005 1 (50mg)</description>
    <arm_group_label>PMK-S005 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PMK-S005 2</intervention_name>
    <description>Drug : PMK-S005 2 (100mg)</description>
    <arm_group_label>PMK-S005 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PMK-S005 3</intervention_name>
    <description>Drug : PMK-S005 3 (150mg)</description>
    <arm_group_label>PMK-S005 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over 19 years of age

          -  Accompanied by hypertension, diabetes, ischemic heart disease, arrhythmia,
             dyslipidemia patients who are required to continuous administration of low-dose
             aspirin(100mg)

          -  Patients who get Modified Lanza Score (MLS) 0 in screening period according to
             endoscopic findings

          -  Patients who have stomach or duodenal ulcer scar in screening period according to
             endoscopic findings. But, the cases that scars caused by other disorders or endoscopic
             treatment are excluded

          -  Patients who have no digestive symptoms(except for mild physconia, abdominal pain,
             diarrhea and vomit, nausea-vomiting) in screening period

          -  Signature of the written informed consent

        Exclusion Criteria:

          -  Within 4 weeks prior to screening period, patients who continuously take aspirin or
             NSAIDs

          -  Patient who has hypersensitivity to PMK-S005 and aspirin components or is banned to
             use them

          -  Patients who had a abdominal surgery that affect gastrointestinal motility (Except
             appendectomy and hysterectomy), But, patients who had enterectomy is excluded
             regardless of the time period

          -  Patients who are judged by investigator that they have other upper gastroesophageal
             disease, active/healing-stage peptic ulcer, digestive malignant tumor or Barrett's
             esophagus

          -  Patients with Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD),
             Ulcerative Colitis, Crohn's disease, Zolinger-Ellison syndrome

          -  History of esophagus, liver, pancreas, stomach, colorectal cancer or malignant tumors
             within 5 years

          -  History of malabsorption within 3 months prior to screening period

          -  Patients who have been taken drug that affect the validity within 2 weeks before
             beginning of the clinical test

          -  Patient who is needed continuously to take antithrombotic agents , anti- coagulant ,
             anti- choline agents, prostaglandins , mucosal protective agents , methotrexate,
             antidepressants , iron treat agents during clinical test.

          -  Patients with clinical meaningful laboratory test results

          -  Known alcohol and/or any other drug abuse or dependence

          -  Pregnant or lactating women

          -  Women planning to become pregnant

          -  Within 1 month, patients who have been taken other clinical test drug

          -  Patients who are judged by investigator that participation of the study is difficult
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bundang Seoul University Hospital</name>
      <address>
        <city>Gumi-dong</city>
        <state>Bundang-gu, Seongnam-si, Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>January 20, 2018</last_update_submitted>
  <last_update_submitted_qc>January 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>Recurrent peptic ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

